From The Motley Fool · Motley Fool Transcribing · · 3m
Axogen Q3 2026 Earnings Report Highlights
Axogen reports 26.2% revenue growth with $75.8 million Q3 revenue, $200 million BioCircuit acquisition, and prostate nerve reconstruction plans.
In brief
Axogen reports 26.2% revenue growth with $75.8 million Q3 revenue, $200 million BioCircuit acquisition, and prostate nerve reconstruction plans. Axogen achieved 26.2% Q3 revenue growth to $75.8 million, completed $200 million BioCircuit acquisition, and plans prostate nerve reconstruction market development in 2027…
Q3 Revenue Growth
Axogen reported $75.8 million in Q3 2026 revenue, a 26.2% year-over-year increase driven by strong unit volume demand for Avance Nerve Graft.
BioCircuit Acquisition
Axogen completed a $200 million cash purchase of BioCircuit Technologies on Oct. 1, 2026, integrating NerveTape into its direct sales platform.
Prostate Nerve Reconstruction
Axogen plans to initiate prostate nerve reconstruction market development in 2027 with clinical data showing 80% erectile function recovery and 95% urinary continence.
Breast Market Penetration
Breast reconstruction segment grew 60% year-over-year with 485 active accounts and 590 active surgeons, representing 11% market penetration.
NerveTape Integration
NerveTape is positioned as a faster, easier coaptation aid for direct nerve repair procedures, potentially replacing microsuturing in 40% to 50% of cases.
Payer Coverage Expansion
96% of U.S. covered lives now have access to Avance following additions of 87.6 million commercial and Medicare Advantage lives across major payers.
Clinical Outcomes
80% of prostate patients achieved erectile function recovery defined as SHIM score of 15 or higher at six months post-operation.
2027 Revenue Guidance
Axogen raised full-year 2026 revenue guidance to at least $290 million, including $7 million from BioCircuit, representing 29% projected growth.
Gross Margin Impact
The step-up in value of acquired BioCircuit inventory could negatively impact gross margin in Q4 and full year relative to current expectations.
Nerve-RESTORE Study
Nerve-RESTORE study enrolled first patient in randomized comparison of Avance Nerve Graft and sural nerve autograft for mixed and motor nerve repair.
EMBRACE Study
EMBRACE study start-up underway to evaluate sensory recovery in breast reconstruction with first site initiation planned for Q4.
MATCH Study Results
MATCH study demonstrated motor recovery with Avance was comparable to nerve autograft in mixed and motor nerve reconstruction.
Free Cash Flow
Axogen generated $18.9 million free cash flow through first nine months of 2026, compared to a loss of $5.9 million in prior year period.
2027 NerveTape Projection
Axogen projects $34 million in incremental NerveTape sales for 2027, net of potential internal product cannibalization.
Organic Growth Guidance
Axogen expects organic revenue growth of at least 26% for 2026, excluding BioCircuit contribution.
Prostate Clinical Data
220 patients across 15 sites received prostate nerve reconstruction with Avance, showing 80% erectile function recovery and 95% urinary continence.
What matters most
Axogen achieved 26.2% Q3 revenue growth to $75.8 million, completed $200 million BioCircuit acquisition, and plans prostate nerve reconstruction market development in 2027.
